To investigate whether GOF mutations of TP53 contribute to attenuation of the therapeutic efficacy of osimertinib, we have now examined the sensitivity to and survival during osimertinib treatment for EGFR-mutated lung cancer cell lines engineered to harbor various TP53 mutations, including GOF and non-GOF mutations. This evidence concerns the gene TP53 and lung cancer.